Benjamin L Wright1, Nielsen Q Fernandez-Becker2, Neeraja Kambham3, Natasha Purington2, Shu Cao2, Dana Tupa2, Wenming Zhang2, Sayantani B Sindher2, Matthew A Rank1, Hirohito Kita4, David A Katzka5, Kelly P Shim1, Bryan J Bunning2, Alfred D Doyle6, Elizabeth A Jacobsen4, Mindy Tsai3, Scott D Boyd7, Monali Manohar2, R Sharon Chinthrajah8. 1. Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona; Division of Pulmonology, Phoenix Children's Hospital, Phoenix, Arizona. 2. Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California. 3. Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California; Department of Pathology, Stanford University School of Medicine, Stanford, California. 4. Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona; Department of Immunology, Mayo Clinic Arizona, Scottsdale, Arizona. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 6. Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona. 7. Division of Pulmonology, Phoenix Children's Hospital, Phoenix, Arizona; Department of Pathology, Stanford University School of Medicine, Stanford, California. 8. Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California. Electronic address: schinths@stanford.edu.
Abstract
BACKGROUND & AIMS: Gastrointestinal side effects are common during oral immunotherapy (OIT) and eosinophilic esophagitis (EoE) is a potential complication. We aimed to characterize eosinophilic gastrointestinal responses to peanut OIT, in which peanut protein is given orally, with incremental increases in dose over time. METHODS: Twenty adults with IgE-mediated peanut allergy were randomly assigned to groups given peanut OIT (n = 15) or placebo (n = 5); 1 additional subject withdrew before randomization. Serial gastrointestinal biopsies were collected at baseline (n = 21, 0 weeks), following dose escalation (n = 10, 52 weeks), and during the maintenance phase (n = 11, 104 weeks). Endoscopic findings were characterized using the EoE endoscopic reference score. Biopsies were assessed for eosinophils per high-power field (eos/hpf) and other pathology features using EoE histologic scoring system scores. We performed immunohistochemical analyses of eosinophil peroxidase deposition, quantified using automated image analysis. RESULTS: At baseline, no subjects reported current gastrointestinal symptoms. However, 3 of the 21 subjects (14%) had esophageal peak eosinophil counts ≥15 eos/hpf and all subjects had dilated intercellular spaces (DIS). OIT induced or exacerbated esophageal eosinophilia (EE) at 52 weeks in most subjects (peak eosinophil counts >5 eos/hpf in 6 of 7 patients [86%]; peak eosinophil counts ≥15 eos/hpf in 4 of 7 patients [57%]). One subject met clinicopathologic criteria for EoE and withdrew; no significant changes in esophageal peak eosinophil counts were observed in the placebo group. EE in the OIT group corresponded with significant increases in EoE histologic scoring system scores and deposition of eosinophil peroxidase. In 4 of 6 participants (67%), OIT-induced EE and gastrointestinal eosinophilia resolved by the end of the maintenance phase. Gastrointestinal symptoms were not clearly associated with EE or gastrointestinal eosinophilia. CONCLUSIONS: In this pilot study, we found that peanut OIT-induced EE and gastrointestinal eosinophilia are usually transient and are not always associated with gastrointestinal symptoms. Clinicaltrials.gov no: NCT02103270.
BACKGROUND & AIMS: Gastrointestinal side effects are common during oral immunotherapy (OIT) and eosinophilic esophagitis (EoE) is a potential complication. We aimed to characterize eosinophilic gastrointestinal responses to peanut OIT, in which peanut protein is given orally, with incremental increases in dose over time. METHODS: Twenty adults with IgE-mediated peanut allergy were randomly assigned to groups given peanut OIT (n = 15) or placebo (n = 5); 1 additional subject withdrew before randomization. Serial gastrointestinal biopsies were collected at baseline (n = 21, 0 weeks), following dose escalation (n = 10, 52 weeks), and during the maintenance phase (n = 11, 104 weeks). Endoscopic findings were characterized using the EoE endoscopic reference score. Biopsies were assessed for eosinophils per high-power field (eos/hpf) and other pathology features using EoE histologic scoring system scores. We performed immunohistochemical analyses of eosinophil peroxidase deposition, quantified using automated image analysis. RESULTS: At baseline, no subjects reported current gastrointestinal symptoms. However, 3 of the 21 subjects (14%) had esophageal peak eosinophil counts ≥15 eos/hpf and all subjects had dilated intercellular spaces (DIS). OIT induced or exacerbated esophageal eosinophilia (EE) at 52 weeks in most subjects (peak eosinophil counts >5 eos/hpf in 6 of 7 patients [86%]; peak eosinophil counts ≥15 eos/hpf in 4 of 7 patients [57%]). One subject met clinicopathologic criteria for EoE and withdrew; no significant changes in esophageal peak eosinophil counts were observed in the placebo group. EE in the OIT group corresponded with significant increases in EoE histologic scoring system scores and deposition of eosinophil peroxidase. In 4 of 6 participants (67%), OIT-induced EE and gastrointestinal eosinophilia resolved by the end of the maintenance phase. Gastrointestinal symptoms were not clearly associated with EE or gastrointestinal eosinophilia. CONCLUSIONS: In this pilot study, we found that peanut OIT-induced EE and gastrointestinal eosinophilia are usually transient and are not always associated with gastrointestinal symptoms. Clinicaltrials.gov no: NCT02103270.
Authors: M H Collins; L J Martin; E S Alexander; J Todd Boyd; R Sheridan; H He; S Pentiuk; P E Putnam; J P Abonia; V A Mukkada; J P Franciosi; M E Rothenberg Journal: Dis Esophagus Date: 2017-02-01 Impact factor: 3.429
Authors: Chang Zeng; Simone Vanoni; David Wu; Julie M Caldwell; Justin C Wheeler; Kavisha Arora; Taeko K Noah; Lisa Waggoner; John A Besse; Amnah N Yamani; Jazib Uddin; Mark Rochman; Ting Wen; Mirna Chehade; Margaret H Collins; Vincent A Mukkada; Philip E Putnam; Anjaparavanda P Naren; Marc E Rothenberg; Simon P Hogan Journal: J Allergy Clin Immunol Date: 2018-05-04 Impact factor: 10.793
Authors: R Sharon Chinthrajah; Natasha Purington; Sandra Andorf; Andrew Long; Katherine L O'Laughlin; Shu Chen Lyu; Monali Manohar; Scott D Boyd; Robert Tibshirani; Holden Maecker; Marshall Plaut; Kaori Mukai; Mindy Tsai; Manisha Desai; Stephen J Galli; Kari C Nadeau Journal: Lancet Date: 2019-09-12 Impact factor: 79.321
Authors: Y Jung; T Wen; M K Mingler; J M Caldwell; Y H Wang; D D Chaplin; E H Lee; M H Jang; S Y Woo; J Y Seoh; M Miyasaka; M E Rothenberg Journal: Mucosal Immunol Date: 2015-01-07 Impact factor: 7.313
Authors: Philipp Schreiner; Luc Biedermann; Thomas Greuter; Benjamin L Wright; Alex Straumann Journal: Dis Esophagus Date: 2021-01-11 Impact factor: 3.429
Authors: Shaina H Hasan; Steve Taylor; Shipra Garg; Matthew R Buras; Alfred D Doyle; Cindy S Bauer; Benjamin L Wright; Shauna Schroeder Journal: Pediatr Dev Pathol Date: 2021-06-28